Larry Biegelsen: All right. Thank you very much.
Operator: Our next question comes from Cecilia Furlong with Morgan Stanley. Please proceed with your question.
Cecilia Furlong: Great, good afternoon and thank you for taking the questions, I wanted to ask about your BTK presence portfolio, if you will, what you’ve seen to date with M5+ as for how you’re thinking about just growth in the BTK region, specifically in ’23 versus ’22? And then just how you’re thinking about that business from the longer term? I know you have many aspect, but just how you’re thinking about better sort of targeting that that region going forward?
Doug Godshall: Yes. So we’re – I think what we’ve been running almost like a feasibility exercise with S4 to prove that IVL is really an excellent product for below the knee disease. And yet it requires S4, which is a shorter balloon and most below the knee lesions are quite long. It requires some patience and persistence and luckily many physicians absolutely love IVL and they see that it is safer and more reliable and reproducible for below the knee lesions. So they do the work with a 40 millimeter length balloon. We’re certainly encouraged thus far for the sort of the area just below the popliteal for below the knee, we’re seeing incremental adoption of the smaller diameters, the 3.5 and fours of the M5+ which sort of validates to us.
Do you desire for something longer than the S4? And yet we also see how limited our penetration to date relative to the vast number of patients who have calcified arteries below the knee. I mean it’s one of the most calcified vessel beds and our penetration is relatively speaking more than above the knee lesions. So we’re sort of looking at our chaps, both for further utilization of M5+. But as you indicated, we anticipate having M5+, S4 and at least two other coronary versions in the next 24 months — 12 to 24 months. So we see BTK as a meaningful growth driver to our business in the 2024, 2025 time frame. And that also is one of the reasons why we’re running the BTK II study because we think sort of having a robust data set land right as our portfolio expands, and we have a spectrum of different devices that are custom designed to treat the variety of vessel beds and lesion lengths for the complex disease below-the-knee is we think — is going to end up in a really nice package come 2024, 2025.
Cecilia Furlong: Great. And if I could just follow up on China as well. If you could just speak to in more detail, what you have seen recently, just from COVID pressure from a geographic standpoint where you are at this point from a rollout standpoint. And then just how you’re thinking about time lines at this point too for the locally manufactured product? Cecilia, as you’ve heard, the COVID, they opened up in Q4, COVID swept through very quickly. And that impacted hospitals procedures, patients in Q4 and in Q1. I think what we’re seeing kind of post Chinese New Year is in most of the big cities that’s kind of back to normal because COVID went through so quickly. And hospitals are back to normal. So from a trend standpoint, we’ll have our biggest number of cases in China this week since launch, we’ll have, I think, excellent growth this year compared to last.
